GlassScriptPhysician profile
Maria D Sabio
NPI 1891808879
$15,090.03
in general payments reported to CMS, 2019-2025
43 companies · $3,223 in 2025
The $3,223 reported for 2025 was more than what 80% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,932 · 2020: $1,250 · 2021: $1,611 · 2022: $2,164 · 2023: $2,173 · 2024: $2,737 · 2025: $3,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,796 · Education: $301 · Consulting Fee: $36.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,796.05 |
| Education | $301.25 |
| Consulting Fee | $36.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,198.32 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $2,217.39 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $2,015.99 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Novartis Pharmaceuticals Corporation | $946.41 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $780.76 | 2020-2025 | Takhzyro, Eohilia, Cuvitru |
| Regeneron Healthcare Solutions, INC. | $666.05 | 2019-2025 | Dupixent |
| Genzyme Corporation | $664.03 | 2019-2025 | |
| Genentech USA, INC. | $650.26 | 2019-2025 | Xolair |
| Kaleo, INC. | $522.06 | 2019-2024 | Auvi-Q |
| Optinose US, INC. | $427.30 | 2019-2025 | |
| Pfizer INC. | $333.53 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.62 | 2019-2022 | |
| Mylan Specialty L.P. | $282.53 | 2019-2023 | Yupelri |
| Sanofi-Aventis U.S. LLC | $250.35 | 2022-2024 | |
| Pharming Healthcare, INC. | $171.27 | 2019-2023 | Ruconest |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $161.67 | 2021-2025 | Tezspire |
| Aimmune Therapeutics, INC. | $145.67 | 2022 | |
| Grifols USA, LLC | $143.36 | 2022-2025 | Xembify |
| Octapharma USA, INC. | $135.53 | 2019-2023 | Cutaquig |
| Biocryst US Sales Co., LLC | $116.81 | 2022-2025 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $114.91 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $106.96 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $96.34 | 2025 | Neffy |
| Covis Pharma Gmbh | $70.66 | 2021 | |
| Hikma Pharmaceuticals USA | $64.76 | 2024-2025 | Ryaltris |
| Merck Sharp & Dohme LLC | $61.03 | 2019-2023 | |
| Shire North American Group INC | $56.03 | 2019 | |
| Phadia US INC. | $42.71 | 2023-2024 | Immunocap |
| Hospira, INC. | $37.98 | 2024-2025 | |
| Adma Biomanufacturing LLC | $36.02 | 2024-2025 | |
| Alk-Abello, INC | $32.58 | 2019-2024 | Alternaria Tenuis, Pre-Pen, Standardized Mite D. Farinae |
| Abbvie INC. | $30.70 | 2025 | |
| Horizon Therapeutics Plc | $27.96 | 2019-2023 | Actimmune |
| Ionis Pharmaceuticals, INC. | $26.39 | 2025 | Donidalorsen |
| Paratek Pharmaceuticals, INC. | $25.00 | 2025 | Nuzyra |
| Cycle Pharmaceuticals INC | $21.26 | 2025 | Sajazir |
| Lilly USA, LLC | $19.06 | 2025 | Ebglyss |
| Gc Biopharma USA, INC. | $16.95 | 2025 | Alyglo |
| Azurity Pharmaceuticals, INC. | $16.90 | 2025 | Alvesco |
| Insmed, INC. | $16.79 | 2025 | Brinsupri, Arikayce |
| Viatris Specialty LLC | $16.03 | 2025 | Yupelri |
| Biocryst Pharmaceuticals, INC. | $15.53 | 2020 | |
| Circassia INC. | $14.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Sabio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.